MedCity News September 24, 2024
Vertex Pharmaceuticals is known for its cystic fibrosis drugs, but the company aims to diversify with a pipeline that reaches more therapeutic areas. CEO Reshma Kewalramani explained Vertex’s strategy during the World Medical Innovation Forum in Boston.
Vertex Pharmaceuticals’ breakthrough in cystic fibrosis was a medicine that treats just 4% of patients who have the lung disorder. Today, Vertex’s portfolio of blockbuster CF products spans multiple drugs and drug combinations that can treat 90% of CF patients.
CEO Reshma Kewalramani says Vertex aims to eventually reach all CF patients. But as the company moves closer to this goal, it brings up another part of the company’s strategy: pipeline diversification. The lion’s share of Vertex’s revenue comes from its CF portfolio,...
Today's Sponsors
Today's Sponsor